Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
September 27, 2022 14:57 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a specialty pharmaceutical company involved in the acquisition, development, and...
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes
August 25, 2022 13:30 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) ("Immune" or "IMUN"), a pioneering pharmaceutical company involved in the acquisition, development, and...
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
August 04, 2022 13:19 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and...
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
July 22, 2022 16:26 ET
|
Immune Therapeutics, Inc.
ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and...
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors
June 03, 2022 17:26 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing...
Immune Therapeutics Announces Restructuring Plan
June 04, 2021 12:22 ET
|
Immune Therapeutics, Inc.
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to...
Immune Therapeutics Announces Financing and Debt Restructuring Plan
June 02, 2021 07:00 ET
|
Immune Therapeutics, Inc.
Orlando, Florida, June 02, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUND) (the "Company") announced today that the Company has received and signed a non-binding term sheet to...
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split
May 11, 2021 07:30 ET
|
Immune Therapeutics, Inc.
Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued...
Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week 2021”
January 11, 2021 10:31 ET
|
Immune Therapeutics, Inc.
WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in...
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs
October 20, 2020 11:09 ET
|
Immune Therapeutics, Inc.
WINTER PARK, Fla., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an innovative...